🔗 Share this article

As the United States continues making unprecedented adjustments to its vaccination recommendations, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about COVID-19 vaccinations in the global health crisis and has focused upon possible deaths following Covid immunization in her short position at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Program

Agency leaders were set to reveal sweeping revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, according to reports – a major change that would place the US out of step with many the global community with no evidence for benefit. The planned update has been pushed back until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to lead the office this calendar year.

A New Direction at the Agency

The acting appointment might represent a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad solidify control at the agency – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric immunization guidelines in the US so as to align more like Denmark's approach, a country with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on immunizations – typically the domain of Dr. Prasad, chief of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Expertise

The appointee has no obvious background in pharmaceutical research, regulation or administrative roles, which has been typical for previous leaders of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in running a large organization. She has no expertise in drug approvals.”

Previous commissioners of CBER would “grasp laws and regulations and the research of drug development”, said Janet Woodcock. “Objectively, she doesn’t have the sort of resume that previous people who ran CBER have had.”

CDER has an immense workload at the agency, she stated.

“The public just pays attention on the new drug program, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and more, and every single one need to be managed,” she said. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a major administrative component to the role, which manages more than 5,000 personnel. “It’s a huge management job, if you do it right,” the former official concluded.

Agency Reaction and Disputed Policies

When asked about questions about Dr. Høeg's credentials and whether this appointment signifies greater collaboration among regulatory chiefs on immunizations, a press secretary said that the “concerns rely on flawed assumptions”.

“Her experience is consistent with the functions of her role,” the spokesperson stated, citing the months Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's recently launched priority voucher program, a controversial rapid drug-approval program that allegedly worried her predecessors. “How are these drugs being selected for this expedited pathway? Who is making the decisions?” Howard said. “There is a lot of lack of transparency going on at the FDA right now.”

Overall, he stated, “the agency appears to be shifting towards laxer regulations of most medications, with the exception of shots.”

Public History on Immunizations

Regarding vaccines, Høeg has a clearer, if troubling, past, Howard observe. She published a research paper using non-validated crowd-sourced reports to determine the frequency of heart inflammation following Covid vaccination. She advised the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the new government included changing regulations for recently developed shots and ending “unnecessary” immunizations, she remarked following the vote on a online show. At the agency, Høeg has allegedly floated the idea of barring teenage boys from receiving Covid vaccines.

“She’s an complete dogmatist who starts off with her beliefs and tailors the evidence to retrofit the science in a very disingenuous, fraudulent way,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|